Fig. 1: Response, safety, and survival outcomes in propensity score–matched intermediate-risk AML patients treated with VEN/HMA or IC. | Blood Cancer Journal

Fig. 1: Response, safety, and survival outcomes in propensity score–matched intermediate-risk AML patients treated with VEN/HMA or IC.

From: Genotype-guided comparison of VEN/HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: a multicenter real-world study

Fig. 1

A Response rates in matched cohorts. B Baseline variables predicting differential response to VEN/HMA or IC. C Incidence of myelosuppression-related toxicities in VEN/HMA and IC. D, E Overall survival (OS) and progression-free survival (PFS) in VEN/HMA versus IC groups. F, G Multivariable Cox regression analysis for predictors of OS and PFS.

Back to article page